Integrative analysis of RUNX1 downstream pathways and target genes

Michaud, Joëlle; Simpson, Ken M.; Escher, Robert; Buchet-Poyau, Karine; Beissbarth, Tim; Carmichael, Catherine; Ritchie, Matthew E.; Schütz, Frédéric; Cannon, Ping; Liu, Marjorie; Xiaofeng Shen; Ito, Yoshiaki; Raskind, Wendy H.; Horwitz, Marshall S.; Osato, Motomi; Turner, David R.; Speed, Terence P.; Kavallaris, Maria; Smyth, Gordon K.; Scott, Hamish S.
January 2008
BMC Genomics;2008, Vol. 9, Special section p1
Academic Journal
Background: The RUNX1 transcription factor gene is frequently mutated in sporadic myeloid and lymphoid leukemia through translocation, point mutation or amplification. It is also responsible for a familial platelet disorder with predisposition to acute myeloid leukemia (FPD-AML). The disruption of the largely unknown biological pathways controlled by RUNX1 is likely to be responsible for the development of leukemia. We have used multiple microarray platforms and bioinformatic techniques to help identify these biological pathways to aid in the understanding of why RUNX1 mutations lead to leukemia. Results: Here we report genes regulated either directly or indirectly by RUNX1 based on the study of gene expression profiles generated from 3 different human and mouse platforms. The platforms used were global gene expression profiling of: 1) cell lines with RUNX1 mutations from FPD-AML patients, 2) over-expression of RUNX1 and CBFβ, and 3) Runx1 knockout mouse embryos using either cDNA or Affymetrix microarrays. We observe that our datasets (lists of differentially expressed genes) significantly correlate with published microarray data from sporadic AML patients with mutations in either RUNX1 or its cofactor, CBF β. A number of biological processes were identified among the differentially expressed genes and functional assays suggest that heterozygous RUNX1 point mutations in patients with FPD-AML impair cell proliferation, microtubule dynamics and possibly genetic stability. In addition, analysis of the regulatory regions of the differentially expressed genes has for the first time systematically identified numerous potential novel RUNX1 target genes. Conclusion: This work is the first large-scale study attempting to identify the genetic networks regulated by RUNX1, a master regulator in the development of the hematopoietic system and leukemia. The biological pathways and target genes controlled by RUNX1 will have considerable importance in disease progression in both familial and sporadic leukemia as well as therapeutic implications.


Related Articles

  • A surprising role for FOXO. Niemitz, Emily // Nature Genetics;Oct2011, Vol. 43 Issue 10, p928 

    The article discusses the study regarding the opposite roles of the serine-threonine kinase AKT and the forkhead box O (FOXO) transcription factor in association with acute myeloid leukemia (AML).

  • Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia. Glass, Carolyn; Wuertzer, Charles; Cui, Xiaohui; Bi, Yingtao; Davuluri, Ramana; Xiao, Ying-Yi; Wilson, Michael; Owens, Kristina; Zhang, Yi; Perkins, Archibald // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    The ecotropic virus integration site 1 (EVI1) transcription factor is associated with human myeloid malignancy of poor prognosis and is overexpressed in 8–10% of adult AML and strikingly up to 27% of pediatric MLL-rearranged leukemias. For the first time, we report comprehensive...

  • HOXA9 Gene Expression in Acute Myeloid Leukemia. Li, De-Peng; Li, Zhen-Yu; Sang, Wei; Cheng, Hai; Pan, Xiu-Ying; Xu, Kai-Lin // Cell Biochemistry & Biophysics;Dec2013, Vol. 67 Issue 3, p935 

    Homeobox genes encode the class of transcription factors in vertebrates and are found in clusters called A, B, C, and D on four separate chromosomes. HOXA9 gene is part of the cluster A on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression,...

  • DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Suela, J.; Álvarez, S.; Cifuentes, F.; Largo, C.; Ferreira, B. I.; Blesa, D.; Ardanaz, M.; García, R.; Marquez, J. A.; Odero, M. D.; Calasanz, M. J.; Cigudosa, J. C. // Leukemia (08876924);Jun2007, Vol. 21 Issue 6, p1224 

    We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in...

  • LEUKEMOGENESIS BY THE CHROMOSOMAL TRANSLOCATIONS. MITANI, Kinuko // Leukemia (08876924);Apr97 Supplement 3, Vol. 11, p294 

    The AML1 gene is the most commonly involved transcription factor gene in human leukemias and forms chimeric transcription factor genes, namely, AMLI/MTG8 by the t(8;21), AML1/EVI-1 by the t(3;21), and TEL/AML1 by the t(12;21). The AML1a and AML1b, two isoforms of the AMLI protein, are translated...

  • Significance of MTG8 in Leukemogenesis. Kozu, Tomoko; Komori, Atsumasa; Sueoka, Eisaburo; Fujiki, Hirota; Kaneko, Yasuhiko; Matsui, Takehisa; Uehara, Toshitake; Seino, Yuko; Ishii, Masaru // Leukemia (08876924);Apr97 Supplement 3, Vol. 11, p297 

    MTG8 is a counterpart gene of AML 1 in acute myeloid leukemia with t(8;21) translocation. Most of the coding region of the MTG8 is fused with AML1 runt domain. In normal tissues, the MTG8 is highly expressed in brain, but not in hematopoietic tissues. MTG8 may be important in leukemogenesis as...

  • Characterisation of a compound in-cis GATA2 germline mutation in a pedigree presenting with myelodysplastic syndrome/acute myeloid leukemia with concurrent thrombocytopenia. Hahn, C N; Brautigan, P J; Chong, C-E; Janssan, A; Venugopal, P; Lee, Y; Tims, A E; Horwitz, M S; Klingler-Hoffmann, M; Scott, H S // Leukemia (08876924);Aug2015, Vol. 29 Issue 8, p1795 

    The authors discuss a study on the interaction of the mutant form of the GATA2 transcription factor gene with its binding sites in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with concurrent thrombocytopenia. Topics covered include the performance of western...

  • Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Ostergaard, Pia; Simpson, Michael A; Connell, Fiona C; Steward, Colin G; Brice, Glen; Woollard, Wesley J; Dafou, Dimitra; Kilo, Tatjana; Smithson, Sarah; Lunt, Peter; Murday, Victoria A; Hodgson, Shirley; Keenan, Russell; Pilz, Daniela T; Martinez-Corral, Ines; Makinen, Taija; Mortimer, Peter S; Jeffery, Steve; Trembath, Richard C; Mansour, Sahar // Nature Genetics;Oct2011, Vol. 43 Issue 10, p929 

    We report an allelic series of eight mutations in GATA2 underlying Emberger syndrome, an autosomal dominant primary lymphedema associated with a predisposition to acute myeloid leukemia. GATA2 is a transcription factor that plays an essential role in gene regulation during vascular development...

  • C/EBPa mutations in acute myeloid leukaemias. Nerlov, Claus // Nature Reviews Cancer;May2004, Vol. 4 Issue 5, p394 

    Specific mutations in the gene that encodes the multifunctional transcription factor C/EBP α are frequently associated with acute myeloid leukaemias. Are only a specific subset of the functions of C/EBP α therefore involved in leukaemogenesis?


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics